Carstens Henning, Schumacher Fabian, Keitsch Simone, Kramer Melanie, Kühn Claudine, Sehl Carolin, Soddemann Matthias, Wilker Barbara, Herrmann Daniel, Swaidan Ashraf, Kleuser Burkhard, Verhaegh Rabea, Hilken Gero, Edwards Michael J, Dubicanac Marko, Carpinteiro Alexander, Wissmann Andreas, Becker Katrin Anne, Kamler Markus, Gulbins Erich
Thoracic Transplantation, Thoracic and Cardiovascular Surgery, University Clinic, University of Duisburg-Essen, Essen, Germany.
Faculty of Mathematics and Natural Science, Institute of Nutritional Science, Department of Toxicology, University of Potsdam, Nuthetal, Potsdam, Germany.
Cell Physiol Biochem. 2019;53(6):1015-1028. doi: 10.33594/000000194.
BACKGROUND/AIMS: Pulmonary infections with Pseudomonas aeruginosa (P. aeruginosa) or Staphylococcus aureus (S. aureus) are of utmost clinical relevance in patients with cystic fibrosis, chronic obstructive pulmonary disease, after trauma and burn, upon ventilation or in immuno-compromised patients. Many P. aeruginosa and S. aureus strains are resistant to many known antibiotics and it is very difficult or often impossible to eradicate the pathogens in patient´s lungs. We have recently shown that the sphingoid base sphingosine very efficiently kills many pathogens, including for instance P. aeruginosa, S. aureus or Acinetobacter baumannii, in vitro. In vivo experiments of our group on cystic fibrosis mice indicated that inhalation of sphingosine prevents or eliminates existing acute or chronic pneumonia with P. aeruginosa or S. aureus in these mice. We also demonstrated that sphingosine is safe to use for inhalation up to high doses, at least in mice. To facilitate development of sphingosine to an anti-bactericidal drug that can be used in humans for inhalation, safety data on non-rodents, larger animals are absolutely required.
Here, we inhaled mini pigs with increasing doses of sphingosine for 10 days and analyzed the uptake of sphingosine into epithelial cells of bronchi as well as into the trachea and lung and the systemic circulation. Moreover, we measured the generation of ceramide and sphingosine 1-phosphate that potentially mediate inflammation, the influx of leukocytes, epithelial cell death and disruption of the epithelial cell barrier.
We demonstrate that inhalation of sphingosine results in increased levels of sphingosine in the luminal membrane of bronchi and the trachea, but not in systemic accumulation. Inhaled sphingosine had no side effects up to very high doses.
In summary, we demonstrate that inhalation of sphingosine results in an increase of sphingosine concentrations in the luminal plasma membrane of tracheal and bronchial epithelial cells. The inhalation has no systemic or local side effects.
背景/目的:铜绿假单胞菌(P. aeruginosa)或金黄色葡萄球菌(S. aureus)引起的肺部感染在囊性纤维化患者、慢性阻塞性肺疾病患者、创伤和烧伤患者、通气患者或免疫功能低下患者中具有极其重要的临床意义。许多铜绿假单胞菌和金黄色葡萄球菌菌株对许多已知抗生素耐药,在患者肺部根除病原体非常困难或往往不可能。我们最近表明,鞘氨醇碱鞘氨醇在体外能非常有效地杀死许多病原体,例如铜绿假单胞菌、金黄色葡萄球菌或鲍曼不动杆菌。我们小组在囊性纤维化小鼠上进行的体内实验表明,吸入鞘氨醇可预防或消除这些小鼠中由铜绿假单胞菌或金黄色葡萄球菌引起的现有急性或慢性肺炎。我们还证明,至少在小鼠中,鞘氨醇高剂量吸入使用是安全的。为了促进鞘氨醇开发成可用于人类吸入的抗菌药物,绝对需要非啮齿类大型动物的安全性数据。
在此,我们用递增剂量的鞘氨醇对小型猪进行10天的吸入处理,并分析鞘氨醇进入支气管上皮细胞以及气管、肺和体循环的摄取情况。此外,我们测量了可能介导炎症、白细胞流入、上皮细胞死亡和上皮细胞屏障破坏的神经酰胺和1 -磷酸鞘氨醇的生成。
我们证明吸入鞘氨醇会导致支气管和气管腔膜中鞘氨醇水平升高,但不会导致全身蓄积。吸入鞘氨醇直至非常高的剂量都没有副作用。
总之,我们证明吸入鞘氨醇会导致气管和支气管上皮细胞腔质膜中鞘氨醇浓度增加。吸入没有全身或局部副作用。